Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

BACKGROUND: Small cell lung cancer (SCLC) is a deadly disease with a 5-year survival of less than 7%. The addition of immunotherapy to chemotherapy was recently approved as first-line treatment; however, the improved clinical benefit is modest, highlighting an urgent need for new treatment strategie...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yuanwang, Hao, Yuan, Han, Han, Chen, Ting, Ding, Hailin, Labbe, Kristen E, Shum, Elaine, Guidry, Kayla, Hu, Hai, Sherman, Fiona, Geng, Ke, Stephens, Janaye, Chafitz, Alison, Tang, Sittinon, Huang, Hsin-Yi, Peng, Chengwei, Almonte, Christina, Lopes, Jared E, Losey, Heather C, Winquist, Raymond J, Velcheti, Vamsidhar, Zhang, Hua, Wong, Kwok-Kin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462379/
https://www.ncbi.nlm.nih.gov/pubmed/36472839
http://dx.doi.org/10.1136/jitc-2022-004913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462379/
https://www.ncbi.nlm.nih.gov/pubmed/36472839
http://dx.doi.org/10.1136/jitc-2022-004913

Ejemplares similares